BioMarin Pharmaceutical Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| B1MR34.SA | BBIO | 0NZU.IL | ROIV | 0A3M.IL | ALNY | |
|---|---|---|---|---|---|---|
| Market cap | 55.80B | 15.17B | 14.33B | 27.61B | 25.17B | 21.57B |
| P/E (TTM) | — | — | — | — | 5.1 | 8.1 |
| Forward P/E | — | -225.0 | — | -27.5 | 5.1 | 14.4 |
| Price/book | 0.9 | -5.9 | 8.1 | 6.5 | 1.1 | 6.0 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +3.51% | +24.17% | −43.38% | +85.85% | −13.17% | −63.43% |
| Today | 0.00% | +5.21% | +0.86% | +6.08% | +2.81% | +0.74% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All B1MR34.SA news ›BioMarin Pharmaceutical Inc. (BMRN) Q3 2026 Earnings Call Transcript
BioMarin Pharmaceutical Inc. (BMRN) Q3 2026 Earnings Call November 2, 2026 4:30 PM EST Traci McCarty - Group Vice PresidentAlexander Hardy - President, CEO & DirectorCristin Hubbard - Executive VP & Chief Commercial OfficerGregory Friberg…
More from 1 other outlet
BioMarin Pharmaceutical (NASDAQ:BMRN) Stock Price Target Lowered at Morgan Stanley
Posted by Sarita Garza on Nov 3rd, 2026 Get Our Latest Analysis on BMRN Here are the key news stories impacting BioMarin Pharmaceutical this week: BioMarin Pharmaceutical Inc is a biotechnology company focused on developing and…
BioMarin Pharmaceutical Non-GAAP EPS of $0.23 beats by $0.34, revenue of $1.03B beats by $10M
BioMarin Q3 earnings topped estimates on EPS and revenue as sales jumped 32%. - BioMarin Pharmaceutical press release (BMRN): Q3 Non-GAAP EPS of $0.23 beats by $0.34. - Revenue of $1.03B (+32.7% Y/Y) beats by $10M. - Third Quarter 2026…
HC Wainwright Reaffirms Neutral Rating for BioMarin Pharmaceutical (NASDAQ:BMRN)
Posted by Kim Johansen on Nov 3rd, 2026 BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report)‘s stock had its “neutral” rating reaffirmed by investment analysts at HC Wainwright in a research note issued on Tuesday, Benzinga reports.…
BioMarin Pharmaceutical (NASDAQ:BMRN) Issues FY 2026 Earnings Guidance
Posted by Sarita Garza on Nov 3rd, 2026 BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) updated its FY 2026 earnings guidance on Tuesday. The company provided EPS guidance of 2.800-3.100 for the period, compared to the consensus…
BioMarin Pharmaceutical (NASDAQ:BMRN) reports Q3 2026 in line with expectations but full-year sales guidance misses expectations
Biotech company BioMarin Pharmaceutical BMRNmet Wall Street’s revenue expectations in Q3 2026, with revenue up 32% year on year to $1.02 billion. On the other hand, the company’s full-year revenue guidance of $3.85 billion at the midpoint…
Robert W. Baird Reaffirms Their Hold Rating on BioMarin Pharmaceutical (BMRN)
In a report released yesterday, Jack Allen from Robert W. Baird maintained a Hold rating on BioMarin Pharmaceutical, with a price target of $65.00. The company’s shares closed yesterday at $55.35. According to TipRanks, Allen is an analyst…
BioMarin Pharmaceutical (BMRN): Amicus Acquisition Accelerates Revenue Growth
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) has entered a transformational phase following its $4.8 billion all-cash acquisition of Amicus Therapeutics, completed... The post BioMarin Pharmaceutical (BMRN): Amicus Acquisition Accelerates…
Analysts’ Opinions Are Mixed on These Healthcare Stocks: BioMarin Pharmaceutical (BMRN), Eli Lilly & Co (LLY) and Bristol-Myers Squibb (BMY)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on BioMarin Pharmaceutical (BMRN), Eli Lilly & Co (LLY) and Bristol-Myers Squibb (BMY). Wells Fargo analyst Mohit Bansal assigned a Buy rating to…
BioMarin Pharmaceutical (BMRN) – Research Analysts’ Recent Ratings Updates
Posted by Defense World Staff on Oct 20th, 2026 BioMarin Pharmaceutical (NASDAQ: BMRN) recently received a number of ratings updates from brokerages and research firms: BioMarin Pharmaceutical Inc is a biotechnology company focused on…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- themarketsdaily.com8
- seekingalpha.com4
- theglobeandmail.com3
- defenseworld.net2
- markets.financialcontent.com2
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 24 articles, not a forecast.